Agilent's Sagging Q4 Bioanalytical Sales Include 7 Percent Dip in Life Science Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies today reported a 9 percent drop in fourth-quarter revenues for its Bioanalytical segment, including a 7 percent dip in life science receipts.

The slowing sales in Agilent's Bioanalytical segment contributed to an overall 21 percent drop in company-wide Q4 revenues and an 89 percent decline in net income.

For the fourth quarter ended Oct. 31, 2009, Agilent's Bioanalytical group reported revenues of $544 million compared to $594 million for Q4 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.